TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InMed Pharmaceuticals ( (INM) ) just unveiled an announcement.
On November 18, 2025, InMed Pharmaceuticals announced the successful completion of pharmacokinetic studies in large animal models for its Alzheimer’s disease candidate, INM-901. The studies demonstrated robust bioavailability and no adverse neural or behavioral effects, supporting the potential utility of INM-901 in neurodegenerative disorders. This marks a significant step towards human clinical trials, with preparations underway for a pre-IND meeting with the FDA and further development activities.
The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Underperform.
InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications.
Average Trading Volume: 127,538
Technical Sentiment Signal: Sell
Current Market Cap: $4.63M
For a thorough assessment of INM stock, go to TipRanks’ Stock Analysis page.